Detalhe da pesquisa
1.
A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
J Infect Dis
; 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38487996
2.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
3.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
4.
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Nat Med
; 29(1): 147-157, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36228659
5.
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.
JCI Insight
; 7(6)2022 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192547
6.
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Lancet Microbe
; 3(9): e663-e671, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35907430
7.
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.
Front Immunol
; 13: 795463, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35197971
8.
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
JCI Insight
; 7(7)2022 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192543
9.
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies.
Vaccines (Basel)
; 9(3)2021 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33809415
10.
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
Nat Commun
; 12(1): 4636, 2021 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34330906
11.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Lancet HIV
; 8(8): e474-e485, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34153264
12.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(2): 279-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335322
13.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(2): 270-278, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335323
14.
Demonstrating the potential of a novel spider venom-based biopesticide for target-specific control of the small hive beetle, a serious pest of the European honeybee.
J Pest Sci (2004)
; 93(1): 391-402, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31997983
15.
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Lancet Infect Dis
; 20(7): 816-826, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325038
16.
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(6): 1113, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958800
17.
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(6): 1116, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34021278